PTO/SB/084(10-01)
Approved for use through 10/31/2002, OMB 651-0031
US Patent & Tridemark Office; U.S. DEPARTMENT OF COMMITTEE

	Under the Paperwork Reduction Act of 1995, no persons are:	required to respond to a collection of information unless it contains a valid OMS control number.
Substitute for form 1449A/PTO	Complete if Known	
JUL 2 0 2006	Application Number	10/798,081
	Filing Date	March 11, 2004
	First Named Inventor	Lecanu, Laurent
	Group Art Unit	1632
	Examiner Name	Hama, Joanne
	Aut District Marie	1044 0401164
1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	Attorney Docket No: 1	1941.012051

US PATENT DOCUMENTS				
Examiner USP Document Number Publication Date Name of Patentee or Applicant of cited Document Initial • Publication Date Filing Date				
JH	US-5,192,688	03/09/1993	Switzer III, , et al.	09/25/1991
JH	US-6,172,277	01/09/2001	Tate, B. A., et al.	10/28/1997

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T²

	OTHER	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	T'
JH		"International Search Report and Written Opinion for Application No.	
		PCT/US04/07457, date mailed November 5, 2004", 9 pgs	
		AGGLETON, J P., "The contribution of the amygdala to normal and abnormal emotional states.", Trends Neurosci. 16(8), (1993), 328-333	
		AHN, Y., et al., "Depletion of Intracellular Zinc Induces Protein	
		Synthesis-Dependent Neuronal Apoptosis in Mouse Cortical Culture", Experimental Neurology, 154, (1998), 47-56	
	-	ARENDT, T., et al., "Phosphorylation of Tau, A BETA- Formation, and Apoptosis After in Vivo Inhibition of PP-1 and PP-2A", Neurobiology of Aging, 19 (1), (1998), 3-13	
		BEAL, M B., "Does Impairment of Energy Metabolism Result in Excitotoxic Neuronal Death n Neurodegenerative Illness?", Annals of Neurology, 31(2), (Feb., 1992),119-130	
		BEHL, C., et al., "Neuroprotection Against Oxidative Stress By Estrogens: Structure -Activity Relationship", Molecular Pharmacology, 51, (1997), 535-541	
		BRAAK, H, et al., "Involvement of precerebellar nuclei multiple system atrophy", Neuropathology and Applied Neurobiology, 29(1), (2003), 60-76	
		BROWN, RACHEL C., et al., "Oxidative stress-mediated DHEA formation in Alzheimer's disease pathology", Neurobiology of Aging, 24(1), (2003), 57-65	
		BUTTERFIELD, D A., et al., "Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid B-peptide 1-42", Peptides, 23(7), (2002), 1299-1309	
$\bigvee$		CALHOUN, MICHEAL E., et al., "Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid", <a href="Proc Natl Acad Sci U S A., 96(24)">Proc Natl Acad Sci U S A., 96(24)</a> , (Nov. 23, 1999), 14088-14093	

**EXAMINER** 

DATE CONSIDERED

PTO/SB/08A(10-01)
Approved for use through 10/31/2002, OMB 651-0031
US Patent & Trademerk Office: U.S. DEPARTMENT OF COMMERCE
to of information values in contains a value of the contains and th

Sheet 2 of 5	Attorney Docket No: 1	1941.012US1
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Examiner Name	Hama, Joanne
	Group Art Unit	1632
	First Named Inventor	Lecanu, Laurent
	Filing Date	March 11, 2004
	Application Number	10/798,081
Substitute for form 1449A/PTO	Complete if Known	
	Under the Paperwork Reduction Act of 1995, no persons are	required to respond to a collection of information unless it contains a valid OMB control number

	OTHER	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ť²
JH		CHMIELOWSKA, J., et al., "Single vibrissal cortical column in the mouse	
<b>0</b>		labeled with 2-deoxyglucose.", Exp. Brain Res., 63(3), (1986),607-19	
1		CHRISTEN, YVES, "Oxidative stress and Alzheimer disease", Am J Clin	
		Nutr., 71(2), (2000),621S-629S	
		DE LA TORRE, J. C., "Vascular basis of Alzheimer's pathogenesis.",	
		Ann. N.Y. Acad. Sci., 977, (2002), 196-215	
		DODART, J C., et al., "Does my mouse have Alzheimer disease?",	
		Genes Brain Behav. 1(3), (Aug., 2002),142-55	_
		ENNACEUR, A, et al., "A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data.", Behav. Brain Res., 31(1), (1988), 47-59	
		FILE, S. E., et al., "Validity of head-dipping as a measure of exploration in a modified hole-board.", Psychopharmacologia (Berl), 44(1), (1975), 53-59	
		FLOYD, ROBERT A., "Oxidative stress in brain aging. Implications for	
		therapeutics of neurodegenerative diseases", Neurobiology of Aging, 23(5), (2002), 795-807	
		GOODMAN, YADONG, et al., "Estrogens attenuate and corticosterone	
		exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide	
		toxicity in hippocampal neurons", <u>Journal of Neurochemistry</u> , 66(5), (1996), 1836-1844	
		GREEN, A J., "Cerebrospinal fluid brain-derived proteins in the diagnosis	
		of Alzheimer's disease and Creutzfeldt-Jakob disease", Neuropathology and Applied Neurobiology, 28(6), (2002), 427-440	
		GRIFFITH, OWEN W., "Potent and Specific Inhibition of Glutathione	
l		Synthesis by Buthionine Sulfoximine (S-n-Butyl Homocysteine	1
		Sulfoximine)", The Journal of Biological Chemistry, 254(16), (Aug. 25,	
	ļ	1979),7558-7560	├
		HARDY, JOHN A., et al., "Alzheimer's disease: the amyloid cascade hypothesis.", Science, 256(5054), (Apr. 10, 1992),184-185	
		HOLCOMB, LEIGH, "Accelerated Alzheimer-type phenotype in	
		transgenic mice carrying both mutant amyloid precursor protein and	]
		presenilin 1 transgenes", Nature Medicine, 4(1), (Jan., 1998),97-100	<u> </u>
1/		HSIAO, KAREN, et al., "Correlative memory deficits, Abeta elevation,	
Ψ		and amyloid plaques in transgenic mice", Science, 274(5284), (Oct. 4, 1996), 99-103	

EXA		E D
EAAI	MIN	

PTO/SB/084(10-01)
Approved for use through 10/31/2002, OAB 651-0031
US Patent & Tredemic Office: U.S. DEPARTMENT OF COMMERCE
an of information unless it confidence with a confidence of the con

Sheet 3 of 5	Attorney Docket No: 1	1941.012US1	
·	Examiner Name	Hama, Joanne	
	Group Art Unit	1632	
	First Named Inventor	Lecanu, Laurent	
(Use as many sheets as necessary)	Filing Date	March 11, 2004	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	<b>Application Number</b>	10/798,081	
Substitute for form 1449APTO	Complete il Known		
	Under the Paperwork Reduction Act of 1996, no persons are	required to respond to a collection of ireormation unless it contains a valid OMS control number	

		OTHER	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Exam		Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
			IRIZARRY, MICHAEL C., et al., "APPsw Transgenic Mice Develop Age-	
J	H		related AB Deposits and Neuropil Abnormalities, but no Neuronal Loss in	
			CA1", Journal of Neuropathology and Experimental Neurology, 56(9),	
			(Sept., 1997),965-973	
_			JANUS, CHRISTOPHER, et al., "Transgenic mouse models of	
			Alzheimer's disease", Biochimica et Biophysica Acta, 1502(1), (2000),	
		· · · · · · · · ·	63-75	
		-	JANUS, C, et al., "Transgenic mouse models of Alzheimer's disease.", Physiol Behav., 73(5), (2001), 873-886	
			KHACHATURIAN, ZAVEN S., "Hypothesis on the regulation of cytosol	
İ			calcium concentration and the aging brain", Neurobiol Aging., 8(4), (Jul-	
			Aug, 1987), 345-6	
			KOISTINAHO, MILLA, et al., "Specific spatial learning deficits become	
			severe with age in beta -amyloid precursor protein transgenic mice that	
			harbor diffuse beta -amyloid deposits but do not form plaques", Proc Natl	
			Acad Sci U S A, 98(25), (Dec. 4, 2001),14675-14680	ļ
			LECANU, LAURENT, et al., "Beta-Amyloid and Oxidative Stress Jointly	
			Induce Neuronal Death, Amyloid Deposits, Gliosis, and Memory	
			Impairment in the Rat Brain", Pharmacology, 76(1), (2006),19-33	<del> </del>
			LEE, J., et al., "The formation of PHF-1 and SMI-31 positive dystrophic neurites in rat hippocampus following acute injection of okadaic acid",	
			Neuroscience Letters, 282(1-2), (2000), 49-52	
			LEUTNER, SILKE, et al., "Reduced antioxidant enzyme activity in brains	ļ
			of mice transgenic for human presentilin-1 with single or multiple	
			mutations", Neuroscience Letters, 292(2), (2000), 87-90	
			LEWIS, JADA, et al., "Enhanced neurofibrillary degeneration in	<u> </u>
			transgenic mice expressing mutant tau and APP", <u>Science</u> , 293(5534).	
			(Aug. 24, 2001),1487-1491	
			LOGGI, G., et al., "Morphine effects on mouse locomotor/exploratory	
			activity: test dependency, test reliability, uni- and multi-variate analyses.",	
			Pharmacol. Biochem. Behav., 38(4), (1991), 817-822	L
			LOVELL, M A., et al., "Copper, iron and zinc in Alzheimer's disease	
			senile plaques", <u>Journal of the Neurological Sciences</u> , 158(1), (1998),	
			47-52	<u> </u>
	/		MATSUBARA, E, et al., "Vascular Amyloidosis in Neurodegenerative	
	7		Conditions", <u>Drug News Perspect. 15(7)</u> , (Sept., 2002), 439-444	L

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO/SB/08A(10-01)
Approved for use through 10/31/2002, OMB 651-0001
US Pears & research Office; U.S. DEPARTMENT OF COMMERCE
collection of information urless it contains a wild OMB control number.

Substitute for form 1449A/PTO	Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/798,081	
(Use es many sheets as necessary)	Filing Date	March 11, 2004	
	First Named Inventor	Lecanu, Laurent	
	Group Art Unit	1632	
'	Examiner Name	Hama, Joanne	
Sheet 4 of 5	Attorney Docket No: 1	941.012US1	

 $\Phi_{\mathbf{k}}^{n}(x_{\mathbf{k}}) = \mathbf{G}$ 

_	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
JH		MIYAKAWA, TAIHEI, "Vascular pathology in Alzheimer's disease",	ĺ
		Annals New York Academy of Sciences, 977, (2002), 303-305	ļ
		MORRIS, R., et al., "Developments of a water-maze procedure for	
		studying spatial learning in the rat.", <u>J Neurosci Methods., 11(1),</u> (1984),	
		MUDHER, AMRITPAL, et al., "Alzheimer's disease-do tauists and	
		baptists finally shake hands?", <u>Trends in Neurosciences, 25(1),</u> (Jan., 2002),22-26	<u> </u>
		MULDER, C, et al., "CSF markers related to pathogenetic mechanisms	
		in Alzheimer's disease", The Journal of Neural Transmission, 109(12).	
		(2002), 1491-1498	
	<del> </del>	NAG, S, et al., "Chronic intracerebroventricular exposure to beta-	
		amyloid(1-40) impairs object recognition but does not affect spontaneous	
		locomotor activity or sensorimotor gating in the rat", Exp Brain Res.	
,		136(1), (2001), 93-100	
		NAG, S, et al., "Reduction in somatostatin and substance P levels and	
		choline acetyltransferase activity in the cortex and hippocampus of the rat	
		after chronic intracerebroventricular infusion of beta-amyloid (1-40).",	
		Brain Research Bullentin, 50(4), (1999), 251-262	
		NAGAI, TAKU, et al., "Cognition impairment in the genetic model of	
		aging klotho gene mutant mice: a role of oxidative stress", The FASEB	
		Journal, 17(1), (Jan., 2003),50-52	<u>.                                    </u>
		NITTA, ATSUMI, et al., "beta-Amyloid protein-induced Alzheimer's	
		disease animal model", Neuroscience Letters, 170(1), (1994), 63-66	
		OFFEN, D., et al., "Vasoactive intestinal peptide (VIP) prevents	
		neurotoxicity in neuronal cultures: relevance to neuroprotection in	
		Parkinson's disease", Brain Research, 854(1-2), (2000), 257-262	
		OLARIU, A, et al., "Memory deficits and increased emotionality induced	
		by beta-amyloid (25-35) are correlated with the reduced acetylcholine	
		release and altered phorbol dibutyrate binding in the hippocampus", The	ĺ
		Journal of Neural Transmission, 108(8-9), (2001),1065-1079	
		PRATICO, DOMENICO, et al., "Aluminum modulates brain amyloidosis	
		through oxidative stress in APP transgenic mice", The FASEB Journal,	1
		<u>16(9),</u> (July, 2002),1138-1140	
\/		PRATICO, DOMENICO, et al., "Increased lipid peroxidation precedes	
<b>V</b>		amyloid plaque formation in an animal model of Alzheimer amyloidosis",	[
		The Journal of Neuroscience, 21(12), (June 15, 2001),4183-4187	<u> </u>

EXAMINER DATE CONSIDERED

PTO/SB08A(10-01)
Approved for use through 10/31/2002, CMB 851-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449APTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OAIB control number.  Complete if Known		
	Application Number	10/798,081	
	Filing Date	March 11, 2004	
	First Named Inventor	Lecanu, Laurent	
	Group Art Unit	1632	
	Examiner Name	Hama, Joanne	
Sheet 5 of 5	Attorney Docket No: 1941.012US1		

	OTHER	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JH		SIGURDSSON, E. M., et al., "Bilateral Injections of Amyloid-Beta 25-35 into the Amygdala of Young Fischer Rats: Behavioral Neurochemical, and Time Dependent Histopathological Effects", Neurobiol. Aging, 18(6), (1997), 591-608	:
		SMITH, MARK A., et al., "Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress", <u>Journal of Neurochemistry</u> , 70(5), (1998), 2212-2215	
		SMITH, MARK A., "Oxidative stress in Alzheimer's disease", <u>Biochimica</u> et Biophysica Acta 1502, (2000),139-144	
		STAUFENBIEL, MATTHIAS, et al., "Neuron loss in APP transgenic mice". Nature, 395(6704), (1998), 755-756	
		STEIN, THOR D., et al., "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein Is Associated with Increased Levels of Transthyretin and the Activation of Cell Survival Pathways", The Journal of Neuroscience, 22(17), (Sept. 1, 2002),7380-7388	
		SWITZER III, R C., "Application of silver degeneration stains for neurotoxicity testing", <u>Toxicol Pathol. 28(1)</u> , (Jan-Feb 2000), 70-83	
		THAL, DIETMAR R., et al., "Fleecy amyloid deposits in the internal layers of the human entorhinal cortex are comprised of N-terminal truncated fragments of Abeta", <u>Journal of Neuropathology and Experimental</u> Neurology, 58(2), (Feb., 1999),210-216	
		VOLICER, L., et al., "Involvement of free radicals in dementia of the Alzheimer type: a hypothesis", Neurobiol Aging. 11(5), (Sep-Oct, 1990), 567-71	
		WELLER, R O., et al., "Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain", Neurol Res. 25(6), (Sept 2003), 611-6	
V		WINKLER, DAVID T., et al., "Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy", <u>The Journal of Neuroscience</u> , 21(5), (Mar. 1, 2001), 1619-1627	

EXAMINER /Joanne Hama/

DATE CONSIDERED

02/19/2007